AMLX Amylyx Pharmaceuticals, Inc.
AMLX Amylyx Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Desk view
Market read
POC $13.99 · VWAP $20.51 · +32.6% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 3 others sold $2.9M, Sep 14
Coverage
1 watchlist
AMLX Price Structure
Loading timeframes…
Peers
Every watchlist AMLX belongs to, members best 30-day change first — AMLX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: diluted EPS -$0.39, net income -$43M (SEC filing). Across the print the stock moved +4.4% (close before → first close after).
full note →Against street estimates
How AMLX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
AMLX research tape
66 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.